Ihre Fördermöglichkeiten im 7. EU-Rahmenprogramm (7.RP) für Forschung und Entwicklung Ylva Huber...

Ihre Fördermöglichkeiten im 7. EU-Rahmenprogramm (7.RP) für Forschung und Entwicklung

Ylva Huber

Bereich Europäische und Internationale ProgrammeFFG – Österreichische Forschungsförderungsgesellschaft

Inhalt

• Generelle Gesichtspunkte des 7. EU-Rahmenprogramms

• Health“ und „Food, Agriculture and Fisheries, and Biotechnology“ in der 1. Ausschreibung

• Das Programm „IDEAS“

Inhalt


• „Health“ und „Food, Agriculture and Fisheries, and Biotechnology“ in der 1. Ausschreibung


Budget FP7: für „Common Approach“

Cooperation 32.315Health 6.000

Biotech, Food, Agriculture 1.935Information Society 9.120Nanomaterials Production 3.505Energy 2.300Environment 1.900Transport 4.195Socio-economic Research 610Security and Space 2.750

Ideas 7.460People 4.728Capacities 4.267

Total: 50.521 billion EUR(incl. Joint Research Centre 1,7 Mrd)

Instrumente im 7. RP

7. EU-Rahmenprogramm 6. EU-Rahmenprogramm

Verbundprojekte („Collaborative Projects)

Integrierte Projekte (IP)

Gezielte Forschungsprojekte (STREPs)

Exzellenznetze (NoE) Exzellenznetze (NoE)

Koordinierungsmaßnahmen (CA) Koordinierungsmaßnahmen (CA)

Unterstützungsmaßnahmen (SSA) Unterstützungsmaßnahmen (SSA)

Unterstützung für Ausbildung und Karriereentwicklung (Marie-Curie)

Unterstützung für Ausbildung und Karriereentwicklung (Marie-Curie)

Einzelprojekte im ERC (Programm Ideas)KMU spezifische Maßnahmen KMU spezifische Maßnahmen

Artikel 169 Artikel 169

ERA-NET und ERA-NET PLUS ERA-NET

Gemeinsame Technologieinitiativen (JTI)

Förderhöhen im 7. RP

Abschaffung der Kostenmodelle• Forschung und Entwicklung: Förderung bis zu 75%

- Universitäten - Forschungsorganisationen- Öffentliche Einrichtungen- KMU

• Unternehmen: 50%• Demonstration: bis zu 50%• Grundlagenforschung: bis zu 100%• Specific Support Actions und Coordination Actions: bis zu 100%• Pauschalen für indirekte Kosten sind möglich

Vereinfachung der Abläufe

Technologieplattformen und Gemeinsame Technologieinitiativen

• Mobilisierung europäischer Ressourcen im Bereich Forschung, technologische Entwicklung und Innovation durch Zusammenbringen aller Akteure eines definierten Forschungsbereiches (Industrie, KMU, Universitäten, Endverbraucher)

• Industriegetrieben

• Gemeinsame Definition und Erstellung einer strategischen Forschungsagenda (mittel- bis langfristig)

= Input zur Entwicklung der thematischen Programme im 7. RP

• Einige wenige werden als Gemeinsame Technologieinitiativen (Joint Technology Initiatives) etabliert

• Neuer Weg zur Realisierung von public-private partnerships auf EU-Ebene mit definierter rechtlicher Struktur

Inhalt


• Ausschreibungsthemen zu „Health“ und „Biotechnologies, Agriculture, Food and Fisheries“


• Nächste Schritte

Ziele: Verbesserung der Gesundheit der europäischen Bevölkerung Stärkung der europ. Industrie/Firmen

im Bereich Gesundheit Blick auf globale Gesundheitsfragen

(z.B. Epidemien

Schwerpunkte: Translationale Forschung (Grundlagenforschung klinische

Anwendung) Neue Therapien (Entwicklung und Validierung) Methoden zur Gesundheitsförderung, Krankheitsprävention Diagnostische Instrumente und medizinische Technologien Effiziente Gesundheitssysteme

Thema 1- Gesundheit

(6.050 Mio. Euro)

Theme 1: HEALTH

(6.000 Mio. €)

Activities

Biotechnology, generic tools and technologies for human health1

Translating research for human health 2

Optimising the delivery of health care to European Citizens3

Other Actions across the Health Theme4

High-throughput research

Unifying human and model organism genetic variation databases Temporal and spatial proteomics to study biological processes relevant to

human health Groundbreaking techniques for DNA sequencing and genotyping 2. Call: SME-driven collaborative research projects for developing tools and technologies for high-

throughput research

Detection, Diagnosis and Monitoring Development of a hybrid imaging system Novel optical methodologies for detection, diagnosis and monitoring of disease or

disease-related processes Novel targeted imaging probes for early in vivo diagnosis and/or evaluation of response to

therapy In vivo image-guidance for cell therapy 2. Call : Standardisation and improvement of pre-analytical procedures for in vitro diagnostics High throughput molecular diagnostics in individual patients for genetic diseases with

heterogeneous clinical presentation

Biotechnology, generic tools and technologies for human health (1)1

Predicting suitability, safety and efficacy of therapies

Thema zum Großteil durch Innovative Medicines Initiative (IMI) abgedeckt!

Novel alternative testing strategies for use in pharmaceutical discovery and development

Bottlenecks in reduction, refinement and replacement of animal testing in pharmaceutical discovery and development

Promotion, development, validation, acceptance and implementation of QSARs (quantitative structure-activity relationship) for toxicology

Alternative testing strategies for the assessment of the toxicological profile of nanoparticles used in medical diagnostics

In silico modelling for ADMET outcomes


Innovative therapeutic approaches and interventions Development and production of new generation antibodies Innovative approaches for the development of vaccines for young children Immunotherapy of human food allergies

2.Call:

Development of emerging gene therapy tools and technologies for clinical application

Stem cell lines for cell-based therapies. Development of stem cell culture conditions. Stem cells for kidney regeneration. Adding value to EU stem cell therapy research: scientific communication and

future perspectives.


Large-scale data gathering

Networking biobanking initiatives across Europe: developing standards and norms for existing and future human sample biobanks

Molecular epidemiological studies in existing well characterised European (and/or other) population cohorts

Comparative studies of genetic variation in humans: towards a reference population in Europe

Characterisation and variability of the microbial communities in the Human Body Structure-function analysis of membrane-transporters and channels for the

identification of potential drug target sites High throughput analysis of lipids and lipid-protein interactions Genome-wide association studies in mammalian non-rodent models for the

identification of genes relevant to human health and disease

Translating research for human health (1)2.1. INTEGRATING BIOLOGICAL DATA AND PROCESSES

LARGE-SCALE DATA GATHERING, SYSTEMS BIOLOGY 2

Systems biology

A system approach to eukaryotic unicellular organism biology Modelling of T-cell activation Fundamental approaches to stem cell differentiation Developing an integrated in vitro, in vivo and systems biology modelling approach to

understanding apoptosis in the context of health and disease

2. call:

Multidisciplinary fundamental genomics and molecular biology approaches to study basic biological processes relevant to health and diseases

Coordination and Support Actions in large-scale data gathering and systems biology Traditional Chinese Medicine in post-genomic era. Specific International

Cooperation Action. Targeted region: China.

Translating research for human health (2)2.1. INTEGRATING BIOLOGICAL DATA AND PROCESSES

LARGE-SCALE DATA GATHERING, SYSTEMS BIOLOGY 2

Brain and related diseases

Stroke and mechanisms underlying ischemic brain damage Coding in neuronal assemblies Neurobiology of anxiety disorders Memory loss: underlying mechanisms and therapy From basic spinal mechanisms to spinal cord disease and trauma. Neuron-glia interactions in health and disease

2. Call:

Restorative approaches for therapy of neurodegenerative diseases. From mood disorders to experimental models. Neuronal mechanisms of vision and related diseases. Childhood and adolescent mental disorders. Specific International Cooperation

Action. Target regions: Eastern Europe and Central Asia and Western Balkans.

Translating research for human health (3) 2.2. RESEARCH ON THE BRAIN AND RELATED DISEASES, HUMAN

DEVELOPMENT AND AGEING2

Human Development and Ageing

Novel approaches to reconstitute normal immune function at old age. Termination of developmental processes and their reactivation in adult life Biomarkers of ageing. Increasing the participation of elderly in clinical trials. Research on human development and/or healthy ageing across the EU

Translating research for human health (4)2.2. RESEARCH ON THE BRAIN AND RELATED DISEASES, HUMAN

DEVELOPMENT AND AGEING2

Anti-microbial drug resistance including fungal pathogens

2. Call: Novel targets for drugs against Gram negative bacteria. Host-pathogen interactions in infections by Streptococcus pneumoniae. An integrated platform for development and clinical evaluation of point-of-care

diagnostic devices for microbial detection, antibiotic susceptibility determination and biomarkers

Molecular epidemiology to control nosocomial and community spreading of highly virulent multi-drug resistant strains of bacterial pathogens.

Health and economic cost of antimicrobial resistance. Conference on genetic and biochemical tools for postgenomic physiological analysis

of Staphylococcus, in particular MRSA.

Translating research for human health (5) 2.3. TRANSLATIONAL RESEARCH IN MAJOR INFECTIOUS DISEASES:

TO CONFRONT MAJOR THREATS TO PUBLIC HEALTH2

HIV, AIDS, malaria and tuberculosis

HIV/AIDS Drug Discovery and Preclinical Development Highly innovative approaches for research into host-pathogen interaction in tuberculosis Development of fast tests for the diagnosis of Multi-Drug-Resistant strains of HIV, malaria

and tuberculosis and of latent tuberculosis infection (LTBI). Addressing knowledge gaps in pregnancy malaria. New HIV Vaccines inducing broadly-reactive neutralising antibodies.

2. Call:

Network on HIV and anti-HIV drug resistance HIV and Hepatitis co-infection Blocking the transmission of malaria: the mosquito vector target. European network for study and clinical management of TB drug resistance. Support platform for the development of PRD vaccines Highly innovative research in HIV/AIDS, malaria and tuberculosis between Indian and

European partners. (SICA, Targeted Region: India) Coordination of European research activities with global initiatives, including Public-Private-

Partnerships (SICA; Targeted Regions: ICPC). Next generation of researchers for HIV/AIDS, malaria, tuberculosis and neglected infectious

diseases (SICA; Targeted Regions: ICPC).



Potentially new and re-emerging epidemics

Development of broadly protective influenza vaccine candidates. Identifying immunological mechanisms of protection for influenza vaccines Standardisation of immunological assays including surrogate markers for evaluation of new

influenza vaccines in clinical trials Innovative point-of-care diagnostic tests for influenza. Development of additional treatment strategies for patients suffering from highly pathogenic

influenza. Development of pandemic influenza containment and mitigation strategies. Supporting highly innovative inter-disciplinary research on influenza. Influenza research in collaboration with Asian partners. (SICA, Targeted regions: Asia)

2. Call:

Strengthening research on prediction, identification, modelling and surveillance of newly emerging infectious diseases in humans.

Definition of research needs and priorities in Europe in the area of Emerging Infectious Epidemics.



Cancer• Translating the knowledge on non-coding RNAs linked to the aetiology of cancer into novel

diagnosis and therapy strategies.

• Translating clinical ’omics’-technology (genomics, proteomics, metabolomics) into innovative cancer biomarkers aiding in early diagnosis, prognosis and treatment selection of cancer patients.

• Genomic instability and genomic alterations in pre-cancerous lesions and/or cancer.

• Novel cancer screening methods.

• Optimising research on end of life care of cancer patients.

• Understanding and fighting metastasis.

• Improving targeted drug delivery to cancer cells for cancer therapeutics other than gene therapy

• Developing high-throughput bioassays and models for human cancers in lower species.

2. Call:

• Innovative combination clinical trials for multimodal cancer therapy.

• Role of inflammation in tumour initiation and progression.

• Epidemiology of gene-environment interactions involved in carcinogenesis.

• Translating the hypoxic tumour microenvironment.

• ERA-NET on optimisation of the use of cancer registries for cancer research purposes

• Studying cancer aetiology in Latin America. (SICA)

Translating research for human health (8)TRANSLATIONAL RESEARCH IN OTHER MAJOR DISEASES2

Cardiovascular Disease

Molecular basis of the inflammatory response and associated vascular remodelling in arteriosclerosis.

Vascular remodelling in aneurysmal disease. Combating stroke.

2. Call: Congenital pathologies affecting the heart. Cell therapies for the treatment of heart ischemia. Organ imaging in CVD. Integrating pharmacogenomic approaches into the treatment of CVD.

Translating research for human health 9)TRANSLATIONAL RESEARCH IN OTHER MAJOR DISEASES2

Diabetes and Obesity

Early processes in the pathogenesis of type 1 diabetes and strategies for early prevention. Combined forms of diabetes in children.

Insulin resistance as a key factor in the development of diabetes and metabolic syndrome. Pathophysiological mechanisms related to excess fat.

A road-map for diabetes research.

2. Call:

Nutritional signals and the development of new diabetes/obesity therapeutic agents. Markers and treatment for diabetic neuropathy complications. Geno- and phenotypical differentiation of type 2 subjects and monogenic subjects. Use of beta cell imaging in diabetes mellitus.


Rare Diseases

Natural course and pathophysiology of rare diseases. Research capacity-building in the field of rare diseases.

Other Chronic Diseases

Osteoarthritis. Inflammatory bowel disease. Osteoporosis: signalling pathways in bone formation and homeostasis. Genetic factors of Osteoporosis. Intervertebral disc degeneration: prevention and repair. Innovative concepts in chronic obstructive pulmonary disease pathogenesis (COPD). Hearing impairment and degeneration. Impairment of touch and proprioception at old age. Visual impairment and degeneration.

2. Call: Understanding and combating age-related muscle weakness. Translational research aiming for a treatment of urinary incontinence. Early processes in the pathogenesis of chronic inflammatory diseases.


Translating clinical research into clinical practice including better use of medicines, and appropriate use of behavioural and organisational interventions and health therapies and technologies

2.call:

Implementation of research into healthcare practice Self-medication and patient safety Patient Safety Research Network Improving clinical decision making Better use of medicines. Continuity of clinical care. Patient self-management of chronic disease.

Quality, solidarity and sustainability of health systems

2.call:

Evaluation of disease management programmes Health systems and long term care of the elderly Mobility of health professionals Health care human resource planning in nursing. Clinician working time and patient safety. Health outcome measures and population ageing. Trends of population health European system of Diagnosis-related groups (DRG)

Optimising the delivery of health care to European Citizens (1)3

Enhanced health promotion and disease prevention

2.call: Promoting healthy behaviour in children and adolescents Interventions addressing the gradient of health inequalities Public health interventions addressing the abuse of alcohol. Evaluation of suicide prevention strategies across and within European countries. Improve vaccination coverage

Horizontal Coordination and Support Actions across “Optimising the Delivery of Health Care to European Citizens

2.call: Disease networks of centres of reference. Effectiveness of health investments. Patient mobility and access to information. Brokering research into policy. A road-map for ageing research. Health Services Research conference Mental health research conference. Public Health intervention research conference


Specific International Cooperation Actions for Health System Research

2.call: Epidemiological investigations into long-term trends of population health as

consequence of socio-economic transitions, including life-style induced health problems. SICA (Mediterranean Partner countries, Russia, Eastern European and Central Asia)

Universal and equitable access to health care and health financing. SICA (MCP, ACP, Asia and Latin America)

Health care intervention research – optimising hospital care. SICA (Western Balkans.)

Health care intervention research – improving pre-natal and maternal care. SICA (ACP and Mediterranean Partner Countries)


Coordination and Support Actions across the Theme • Reinforcing the network of National Contact Points (NCP) for the Seventh Framework Programme

under Health Theme by promoting transnational co-operation.)

• Promoting participation of high-technology research intensive SMEs, operating in the biomedical engineering and other medical technology sectors´relevant to Health Theme.

• Assessment and valorisation of project outcome for hightechnology and research intensive SME participating to Framework Programmes of Research in the healthcare sector.

• Science communication actions.

• Initiatives to foster dialogue and debate on health research issues of interest to the public.• Studies on the impact of EU legislation on health research and related developments and

applications.

2.call:

• Promotion and facilitation of international cooperation in areas relevant to the objectives of this theme. (SICA, ICPC)

Responding to EU policy needs (2.call)

Paediatric medicinal products, Drug safety research, Living and work conditions, Health statistics, Tobacco Control

Other Actions across the Health Theme4

Example „Innovative Medicines“ - en route to a „Joint Technology Initiative“

Accelerated Development of safe and more effective medicines

Revitalization of the the biopharmaceutical research and development (R&D) environment for Europe to become more competitive

Improving the collaboration between all relevant actors from public and private organisations (public-private partnerships)

Draft and Implementation of a European Research Agenda:

Second version of the Strategic Research Agenda published recently

First Calls expected for end of 2007/beginning of 2008

http://europa.eu.int/comm/research/fp6/index_en.cfm?p=1_innomed

http://rp7.ffg.at/RP7.aspx_param_target_is_116120.v.aspx

« Innovative Medicines »

2. version of the « Strategic Research Agenda »:

4 main topics:

Safety: Early safety evaluation and risk assessment, creation of a European Centre

for Drug Safety

Efficacy: Predictive pharmacology, biomarker identification and validation, patient

recruitment and risk assessment

Knowledge Management: New technologies to control and analyse enormous quantities of information in

an integrative and predictive way

Education and Training: Bridge gaps in expertise required to strengthen the biopharmaceutical R&D

process, creation of a European Medicines Research Academy

Technologieplattform « Innovative Medicines »

Contact in Austria:

Univ. Prof. Dr. Hans Georg Eichler, Vice Rector of the Medical University in Vienna [email protected]

mailto:[email protected]

Thema 2 - Lebensmittel, Landwirtschaft,

Fischerei und Biotechnologie

(1.935 Mio Euro)

Ziel: Aufbau einer “wissensgestützten Bio-Wirtschaft”

Schwerpunkte: Sicherere, gesündere und hochwertigere Lebensmittel Tierschutz Nachhaltige Produktion und Verwendung nachwachsender Bio-

Rohstoffe Epizoonosen und Zoonosen Lebensmittelbedingte Dysfunktionen Nachhaltigkeit und Sicherheit der landwirtschaftlichen Erzeugung

und der Fischerei

Thema 2 - Lebensmittel, Landwirtschaft, Fischerei und Biotechnologie

Nachhaltige Erzeugung und Bewirtschaftung der biologischen Ressourcen aus Böden, Wäldern und der

aquatischen Umwelt1

“Vom Tisch zum Bauernhof”: Lebensmittel, Gesundheit und Wohlergehen2

Biowissenschaften und Biotechnologie im Dienste nachhaltiger Non-food-Erzeugnisse und Verfahren3

• Development of new tools and processes to support R&D in crop plants: molecular breeding• Mining genomics information of farm animals to generate new information on the genetic

basis of phenotypes important to sustainable animal production • Development of genetic systems for crop improvement through a systems biology approach• Development of technologies and tools for the exploitation of livestock genome• Using new technologies to identify (re-)emerging pathogens from wildlife reservoirs• Annual food crops with improved tolerance to multiple abiotic stresses • Genomics for cereal improvement for food, feed and non-food uses • Development of more efficient risk analysis techniques for pests and pathogens of

phytosanitary concern• Reducing the need for external inputs in high-value protected horticultural and ornamental

crops• Developing new methods for valuing and marketing of currently non-marketable forest goods

and services• Coordination of Agricultural Research in the Mediterranean• Reduction of N excretion in ruminants• From capture based to self-sustained aquaculture• Breeding tools for improved livestock products • The farm of tomorrow • GMO cost-effective and crop-specific co-existence measures• (...)

Nachhaltige Erzeugung und Bewirtschaftung der biologischen Ressourcen aus Böden, Wäldern und der

aquatischen Umwelt1

• Smart control for improved food and feed technologies (Large collaborative project)

• Assessment and improvement of existing food and feed technologies (Small collaborative project)

• Nano-devices for quality assurance, food safety and product properties(Small collaborative projects)

• Exposure to food additives, flavourings, and migrants coming from food contact materials – dietary intake models (Large collaborative project)

• Innovative and safe packaging (Small collaborative project)• Post Market Monitoring of the effect of GM food and feed on human and animal

health (Small collaborative project)• Converging technologies and their potential for the food area (Small

collaborative project)• Detecting contaminants in the Food and Feed Chain• (…)

“Vom Tisch zum Bauernhof”: Lebensmittel, Gesundheit und Wohlergehen2

• ENGERGY PLANTS – Novel plants for energy production (Small collaborative project)

• GREEN OIL: Plants providing oils for the future (Large collaborative project)• BIO-VET-Pharming: Plant made recombinant pharmaceuticals for animals

(Network of Excellence)• FOREST PRODUCTS – New forest based products and processes (Large

collaborative project)• GREEN FACTORY – The expression and accumulation of valuable industrial

compounds in plants (Large collaborative project)• Improved Microbes – Metabolic engineering and modelling (Coordination and

Support Action)• IMPROVED MICROBES for the Environment – Microbial gene expression under

conditions of stress (Large collaborative project)• ANIMAL BY PRODUCTS - Nove methods of treatment of animal by products

for the production of substances with biologically valuable functional properties (Small collaborative project)

• And many more….

Biowissenschaften und Biotechnologie im Dienste nachhaltiger Non-food-Erzeugnisse und Verfahren3

EuropäischeTechnologie-Plattformen im Bereich Lebensmittel, Landwirtschaftund Biotechnologie

Plants for the Future: http://www.epsoweb.org/Catalog/TP/index.htm

Food for Life:http://etp.ciaa.be/asp/home/welcome.asp

Global Animal Health:http://www.ifahsec.org/Europe/EUPlatform/Platform.htm

Farm Animal Breeding and Reproduction:http://www.fabretp.org/

http://www.epsoweb.org/Catalog/TP/index.htm

http://etp.ciaa.be/asp/home/welcome.asp

http://www.ifahsec.org/Europe/EUPlatform/Platform.htm

http://www.fabretp.org/

Weitere relevante Themen der 1.Ausschreibung aus anderen Bereichen

Information and Communication Technologies: Objective ICT-2007.5.3: Virtual Physiological Human

Nanosciences, Nanotechnologies, Materials and new ProductionTechnologies:„Creation of a critical and commented database on the health, safety and environmental impact of nanoparticles“„Process intensification in chemicals production“

„Substantial innovation in the European medical industry: development ofnanotechnology-based systems for in-vivo diagnosis and therapy (in Coordination with topic HEALTH-2007-2.4.1-7 and HEALTH-2007-1.2-3 in Theme 1 "Health")

Inhalt


• Health“ und „Food, Agriculture and Fisheries, and Biotechnology“ in der 1. Ausschreibung


23. November 2006Medizinische Universität Graz

/45 Y.Huber / FFG-EIP

Das Programm IDEAS – ein Überblick

Ziele des Spezifischen Programms IDEAS

Rolle des European Research Council (ERC)

Förderlinien



Worum geht es beim Spezifischen Programm IDEAS?

Grundlagenorientierte Spitzenforschung (Pionierforschung)

Alle Forschungsbereiche

Umsetzung durch European Research Council ERC



Forschung an den Grenzen des Wissens (Pionierforschung)

riskant interdisziplinär schwer voraussagbar in ihrer praktischen Anwendung

Vermeidung unzeitgemäßer Unterscheidungen:

Grundlagenforschung - angewandte Forschung Wissenschaft -Technologie traditionelle Disziplinen



Wozu Pionierforschung?



Welche Rolle spielt der ERC?

Hebelwirkung -> strukturelle Verbesserung im Europäischen Forschungssystem

Erhöhung der Exzellenz, Dynamik und Kreativität im Bereich Grundlagenforschung

Stärkung vorhandener Potentiale “an den Grenzen des Wissens”

Einziges Evaluierungskriterium: EXZELLENZ

Mittel des spezifischen Programms IDEAS werden für die Aktivitäten des European Research Council (ERC) eingesetzt



ERC – Struktur und Organisation

Forschungsrat (Scientific Council) Unabhängige Festlegung der ERC-Strategie, wissenschaftlicher

Zielsetzungen, Abwicklung Unterstützt durch Agentur (Dedicated Implementation Structure)

Agentur (Dedicated Implementation Structure) Praktische Implementierung und operatives Management

Europäische Kommission stellt die finanziellen Mittel zur Verfügung sorgt für Autonomie des ERC



ERC - Wissenschaftliche Schwerpunkte

Physikalische und technische Wissenschaften

Lebenswissenschaften

Sozial- und Geisteswissenschaften



ERC – Panels

20 Scientific Panels

20 Panel-Vorsitzende(International anerkannte WissenschafterInnen und ForscherInnen)

200 Panel-Mitglieder(WissenschafterInnen und ForscherInnen aus den jeweiligen Fachgebieten)

1000 - 2000 GutacherInnen

(Consultation letter an Europäische Forschungsorganisationen)



Welche Förderschienen gibt es?

ERC Starting Independent Researchers Grants(ERC Starting Grant)

ERC Advanced Investigator Grants(ERC Advanced Grant)



ERC Starting Grants

Unterstützt werden exzellente Forschende aller Nationalitäten, die ihr erstes selbständiges ForscherInnen-Team in Europa etablieren wollen. Der Weg in die Unabhängigkeit wird unterstützt

Ausschreibung: 22. Dezember 2006 Einreichfrist: April 2007 für die erste Stufe

ERC Advanced Grants

Für exzellente ForscherInnen und WissenschafterInnen, die bereits eine gewisse Unabhängigkeit erlangt haben -> als Folgeprogramm des “Starting Grants” zu verstehen

Ausschreibung: Sommer 2007 Einreichfrist: Anfang 2008



ERC Starting Grants

Projektvorschläge werden von einzelnem/r Forscher/in (“Principal investigator”) eingereicht.

Durchführung der Projekte: transnationale oder nationale Teams

Teamleiter: jede Nationalität

befindet sich in einer Forschungseinrichtung in Europa (EU25, Kandidatenländer, assoziierte Länder)

Teammitglieder: jede Nationalität

Verträge werden zwischen dem ERC und der Gasteinrichtung des Teamleiters abgeschlossen, die für das unabhängige Arbeiten des Teams garantieren muß.



ERC Starting Grants - wer reicht ein?

TeamleiterIn (“Principal Investigator”)

Über 2, weniger als 8 Jahre Forschungserfahrung nach Abschluß des Doktorats.

Teamleiter darf nur in einem Starting Grant – Projekt tätig sein. Keine Beschränkungen bei der Wahl der Projektinhalte. Es muß das erste unabhängige Team sein. Fähigkeit, eigenes Team zu etablieren.



ERC Starting Grants - Evaluierungskriterien

1. Principal Investigator: Potential to become a world class research leader Quality of research output Intellectual capacity and creativity

2. Quality of the proposed research project Ground-breaking nature of the research Potential impact Methodology

3. Research Environment Transition to independence Host institution (normally applicant legal entity) Participation of other legal entities



ERC – weitere Information

Kontakt: Ralf König [email protected] +43 (0)57755 - 4601 http://rp7.ffg.at/erc

http://rp7.ffg.at/erc

http://erc.europa.eu

http://cordis.europa.eu/fp7/ideas.htm

http://ec.europa.eu/research/future/index_en.cfm

mailto:[email protected]

http://rp7.ffg.at/

http://rp7.ffg.at/

http://rp7.ffg.at/erc

http://erc.europa.eu/

http://cordis.europa.eu/fp7/ideas.htm

http://ec.europa.eu/research/future/index_en.cfm

Vielen Dank für Ihre Aufmerksamkeit &

viel Erfolg für Ihre Projekte im 7. Rahmenprogramm!

Ihre Fördermöglichkeiten im 7. EU-Rahmenprogramm (7.RP) für Forschung und Entwicklung Ylva Huber...

Documents

Transcript of Ihre Fördermöglichkeiten im 7. EU-Rahmenprogramm (7.RP) für Forschung und Entwicklung Ylva Huber...